> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lilly’s Oral GLP-1 Maintains Weight Loss After Switch
- URL: https://www.fdaweb.com/lillys-oral-glp-1-maintains-weight-loss-after-switch/
- Published: 2025-12-18T12:00:00.000Z
- Updated: 2026-09-14T15:29:36.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5160412

An Eli Lilly investigational oral obesity drug helped patients largely maintain weight loss after transitioning off injectable incretin therapies, marking what the company describes as the first Phase 3 evidence supporting a switch from weekly injections to a daily pill. Lilly says that its once-daily oral GLP-1 receptor agonist orforglipron met the primary and all key secondary endpoints in the ATTAIN-MAINTAIN trial, a 52-week study evaluating weight maintenance following prior treatment with injectable Wegovy (Novo Nordisk's semaglutide) or Zepbound (Lilly's tirzepatide).

In the study, patients who had previously lost weight on Wegovy or Zepbound and were switched to orforglipron maintained nearly all of their earlier weight reduction, while those switched to placebo regained significantly more weight, the company says.

Participants transitioning from Wegovy to orforglipron maintained all but an average of 0.9 kilograms of their prior weight loss at 52 weeks, Lilly says. Those switching from Zepbound maintained their weight loss with an average difference of 5.0 kilograms. In contrast, placebo-treated patients regained roughly 9 kilograms by 24 weeks in post-hoc analyses.

The trial enrolled 376 patients who had completed the SURMOUNT-5 head-to-head study of Zepbound versus Wegovy and had reached a weight-loss plateau. Patients were re-randomized to receive oral orforglipron or placebo as maintenance therapy.

Lilly has already submitted an orforglipron NDA for the treatment of obesity and overweight adults. The drug has also received a Commissioner’s National Priority Voucher, which can accelerate FDA review timelines.